Beyond the two well-known AD-targeting macromolecular antibodies, bevacizumab, a vascular endothelial growth factor A (VEGF-A)-targeting monoclonal antibody approved in 2004 for metastatic colorectal cancer, was later approved to treat glioblastoma [8]. This evidence concerns the gene VEGFA and glioblastoma.